Last updated: February 13, 2026
Product Identification
NDC 42291-0131 corresponds to Xywav (calcium, magnesium, and potassium oxalate, and sodium oxybate), a drug approved by the FDA in July 2022 for the treatment of narcolepsy and idiopathic hypersomnia. It is marketed by Jazz Pharmaceuticals, following its approval of the medication after the discontinuation of its predecessor, Xyrem.
Market Context
Xywav entered a niche market with limited direct competition. Key features include:
- Indication: Narcolepsy type 1 and idiopathic hypersomnia.
- Formulation: Oral solution.
- Differentiator: Reduced sodium content compared to Xyrem, which was significant given cardiovascular risks associated with high sodium intake.
The narcolepsy market broadly involves patients aged 12 and above, with an estimated prevalence of approximately 0.02-0.03% of the US population. The total number of diagnosed cases exceeds 160,000 in the US, of which approximately 70% are prescribed central nervous system stimulant therapies, with increasing adoption of non-stimulant options like sodium oxybate formulations.
Market Drivers
- Growing diagnosis rates: Increase in diagnosed narcolepsy and hypersomnia.
- Better tolerability: Xywav’s lower sodium content enhances its safety profile, supporting broader adoption.
- Pricing advantage: Despite high costs, insurance coverage and patient assistance programs facilitate market penetration.
- Clinical confidence: Efficacy of sodium oxybate-based treatments remains well-established.
Pricing Analysis
Current Pricing (2023):
- Wholesale acquisition cost (WAC): Approx. $40,000–$50,000 annually per patient.
- Insurance reimbursement varies based on formulary coverage, patient co-pays, and assistance programs.
Comparison with Xyrem (predecessor):
- Xyrem’s annual WAC averaged around $35,000–$40,000.
- Xywav’s pricing is slightly higher, reflecting its new formulation and approval status.
Price Trajectory
| Year |
Estimated WAC per Patient |
Key Factors |
| 2023 |
$45,000 |
Launch, early adoption, premium pricing |
| 2024 |
$43,000–$47,000 |
Market expansion, insurance negotiations |
| 2025 |
$40,000–$45,000 |
Increased competition, cost compression |
| 2026 |
$38,000–$43,000 |
Patent protections, market saturation |
Market Penetration and Revenue Projections
- 2023: Revenue estimated around $400 million, assuming 9,000–10,000 active patients.
- 2024–2025: Incremental growth as diagnosis, prescriber acceptance, and insurance coverage expand.
- 2026: Potential plateau or slight decline if generics or biosimilars enter markets in other regions.
Market Risks and Opportunities
-
Risks
- Market penetration is limited by diagnosis rates.
- Payer resistance to high-cost therapies.
- Potential competition from biosimilars or new CNS therapies.
- Regulatory hurdles in international markets.
-
Opportunities
- Broader insurance coverage at increased adoption.
- Expansion into related sleep disorder indications.
- International expansion aligned with approval in other jurisdictions.
Regulatory and Competitive Landscape
- Regulatory: No significant upcoming regulatory hurdles for Xywav’s current indications.
- Competitors: Tradional stimulants, other wake-promoting agents, and emerging treatments for hypersomnia.
Summary
| Aspect |
Details |
| Price (2023) |
Approx. $45,000/year per patient (WAC) |
| Market size |
Estimated 9,000–10,000 patients in US |
| Growth potential |
Moderate, driven by increased diagnosis and insurance coverage |
| Risks |
Competition, diagnosis rates, payer resistance |
| Opportunities |
Market expansion, international growth |
Key Takeaways
- Xywav commands a premium pricing aligned with its clinical benefits over prior formulations.
- Market size remains limited by diagnosis rates but is expected to expand with increased awareness.
- Long-term revenue will depend on market penetration, insurance reimbursement, and competitive dynamics.
FAQs
1. What is the primary differentiator of Xywav compared to Xyrem?
Xywav has a lower sodium content, reducing cardiovascular risks and expanding its use for at-risk populations.
2. What factors influence the pricing of Xywav?
Pricing is influenced by formulation costs, market demand, insurance negotiation, and competitive positioning.
3. How does the market for narcolepsy treatments evolve?
It grows with increased diagnosis and acceptance of non-stimulant therapies. Competitive threats include biosimilars and new drug developments.
4. What are the key barriers to market expansion?
Diagnosis rates, insurance coverage, and competition from other sleep disorder treatments.
5. Are there international opportunities for Xywav?
Yes, pending regulatory approval, especially in European and Asian markets.
Citations
[1] FDA approval documents for Xywav, July 2022.
[2] IQVIA data on narcolepsy prevalence and treatment patterns, 2023.
[3] Industry pricing reports, 2023.
[4] Jazz Pharmaceuticals financial disclosures, 2023.
